KBI Biopharma and Selexis SA name curated expert J.D. Mowery their CEO

J.D. Mowery, Chief Executive Officer at KBI Biopharma and Selexis SA
J.D. Mowery, Chief Executive Officer at KBI Biopharma and Selexis SA

KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, announced the appointment of J.D. Mowery as Chief Executive Officer (CEO). Widely respected as an innovative biotech leader with a nearly 25-year track record of successfully inspiring colleagues and building organizations, J.D. Mowery will lead KBI and Selexis into the next chapter of becoming a leader in the next generation of CDMOs that are emerging.

What does J.D bring to KBI and Selexis in the role?

J.D. will leverage his biopharmaceutical industry experience in operations, manufacturing, tech transfer, facility construction, business development, employee growth, and investor relations. Having worked with innovators like Genentech, Celgene, Juno, and most recently, Treadwell Therapeutics, as well as CDMOs Lonza and AGC Biologics, he acquired expertise across diverse modalities including small molecule, biologics, and cell and gene therapy.

J.D. will work closely with JSR leadership to ensure a seamless alignment of goals and continue to identify strategic growth opportunities within the larger JSR ecosystem.

What does the appointment mean for KBI and Selexis?

“Through decades of service, J.D. has devoted his career to working with a clear focus on patient impact through the launch of novel therapies and by providing world-class service to manufacturing and development partners,” said Tim Lowery, President of JSR Life Sciences.

Tim Lowery, President of JSR Life Sciences
Tim Lowery, President of JSR Life Sciences

“As we enter a pivotal growth phase, J.D. will play a crucial role in leading KBI and Selexis and empowering our global teams to succeed through servant leadership. We are confident his commitment to our long-term impact will guide us to greater success,” Tim Lowery said.

“It is an honor to join KBI and Selexis at the perfect inflection point where we can leverage the collective knowledge, scientific expertise, and resources of the entire JSR ecosystem. I’m fortunate to work with an amazingly talented team and energized that our partners will see us positively disrupt the industry as an example of a true next-generation CDMO,” said J.D.

“I look forward to leading KBI and Selexis with a relentless focus on realizing our full potential for our people, partners, and the patients across the globe that we serve together,” said J.D.